Medical Condition News

RSS

PROLOR reports positive DSMB review of long-acting human growth hormone clinical trial

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported that patient enrollment and dosing in the Phase II trial of its long-acting version of human growth hormone (hGH-CTP) are proceeding according to plan, with study completion targeted for mid-year 2011.

14 Feb 2011

SpineSmith to rollout VisuALIF stand alone device for intervertebral body fusion of lumbar spine

SpineSmith, a Texas-based medical device company, today announces the company will begin the national rollout in March of the VisuALIF, following a successful Alpha launch.

14 Feb 2011

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

AVEO Pharmaceuticals, Inc. today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster presentations at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17-19, 2011 at the Orlando World Center Marriott in Orlando, Fla.

14 Feb 2011

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fifth scheduled safety analysis and recommended that the trial continue per the protocol.

14 Feb 2011

FDA accepts King's ACUROX NDA for filing with Priority review classification

Acura Pharmaceuticals, Inc. today announced that it has been informed by King Pharmaceuticals Research and Development Inc. (King) that King's New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets was accepted for filing by the US Food and Drug Administration (FDA) with a Priority review classification and a Prescription Drug User Fee Act (PDUFA) date of June 17, 2011.

14 Feb 2011

Registration open for idiopathic pulmonary fibrosis healthcare summit

The Pulmonary Fibrosis Foundation (PFF) announced today that registration is now open for the IPF Summit 2011: From Bench to Bedside. The conference will feature an innovative two-day continuing medical education (CME) program for physicians, researchers, and other health care professionals. Additionally there will be a separate one-day patient, family member, and caregiver program to address the growing educational needs of the idiopathic pulmonary fibrosis (IPF) community.

14 Feb 2011

Less than one-third of acute stroke patients receive clot-busting drug within 60 minutes of hospital arrival

Every minute counts after the onset of a stroke. The more time that elapses before a patient receives an intravenous drug to help break up the clot that is blocking a blood vessel in the brain, the slimmer the chances of a good outcome.

14 Feb 2011

World's earliest functional prosthetic body parts on Egyptian mummy

Two artificial big toes - one found attached to the foot of an ancient Egyptian mummy - may have been the world's earliest functional prosthetic body parts, says the scientist who tested replicas on volunteers.

14 Feb 2011

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."

14 Feb 2011

Expensive 'high tech' therapy not superior to home training for walking recovery of stroke survivors

Home-based physical therapy to improve the strength and balance of stroke survivors works about as well to get them walking again as treadmill training done in a physical therapy lab, according to the results of a study presented today by a Duke researcher at the American Stroke Association's International Stroke Conference.

14 Feb 2011

Novel technology to diagnose Alzheimer's disease before symptoms appear

UT Southwestern Medical Center scientists have helped develop a novel technology to diagnose Alzheimer's disease from blood samples long before symptoms appear.

14 Feb 2011

Study: Young survivors covered by Medicare Part D often can't afford stroke medications

Young, uninsured stroke survivors or those covered by the Medicare Part D drug benefit often can't afford medications - increasing the risk for future strokes or other cardiovascular disease-related events, according to research presented at the American Stroke Association's International Stroke Conference 2011.

14 Feb 2011

JDR releases research report on Osteonecrosis of the jaw

Osteonecrosis of the jaw is a debilitating bone condition that affects the jaws and occurs as a result of reduced local blood supply to the bone. The literature in this area has been severely limited since most investigations cannot evaluate sufficient numbers of afflicted individuals to accurately determine the incidence of the disease and associated risk factors.

14 Feb 2011

Phase III RISE study of Lucentis for DME meets primary endpoint

Genentech, Inc., a member of the Roche Group, announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness.

14 Feb 2011

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company and its interferon payload technology platform and drug discovery pipeline is featured in the February 7 issue of BioCentury, one of the most widely read publications in the pharma and biotech industries.

14 Feb 2011

CX3CL1 signaling chemical can offer better understanding of Parkinson's disease

Targeting the neuroinflammatory causes of Parkinson's disease with a naturally present brain chemical signal could offer a better understanding of the clinical mechanisms of the disease and open a future therapeutic window, reports a team of researchers from the University of South Florida Department Neurosurgery and Brain Repair and the James A. Haley Veterans' Administration Hospital, Tampa.

14 Feb 2011

Some fat is essential for body function

It's common knowledge that too much cholesterol and other fats can lead to disease, and that a healthy diet involves watching how much fatty food we eat. However, our bodies need a certain amount of fat to function—and we can't make it from scratch.

14 Feb 2011

Study explores levels of burden and depression in caregivers with sensory impairment

When a person experiences impairment or declining health, caregiving typically falls to a family member, most often a spouse. This increased burden can cause burnout, stress, and illness in the caregiver. The health care system focuses first on the client and provides little support for the caregiver.

14 Feb 2011

UH Case Stroke and Cerebrovascular Center increases tPA use for ischemic stroke by 13.5 times

University Hospitals Stroke and Cerebrovascular Center recently reported that it has increased the use of tPA or "clot busting therapy" for ischemic stroke by 13.5 times throughout UH system hospitals since implementing the System Stroke Program. Launched in 2008, SSP sought to increase access to the lifesaving treatment for acute ischemic stroke patients in the 15 counties surrounding Cleveland.

14 Feb 2011

New study establishes link between coronary artery disease and genetic susceptibility

A new study involving researchers at the Scripps Translational Science Institute and Scripps Health patients reveals major scientific progress in understanding the mechanism of heart disease at the molecular and genomic levels. STSI is an initiative of Scripps Health in collaboration with The Scripps Research Institute.

14 Feb 2011

Medical Condition News

PROLOR reports positive DSMB review of long-acting human growth hormone clinical trial

SpineSmith to rollout VisuALIF stand alone device for intervertebral body fusion of lumbar spine

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

FDA accepts King's ACUROX NDA for filing with Priority review classification

Registration open for idiopathic pulmonary fibrosis healthcare summit

Less than one-third of acute stroke patients receive clot-busting drug within 60 minutes of hospital arrival

World's earliest functional prosthetic body parts on Egyptian mummy

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Expensive 'high tech' therapy not superior to home training for walking recovery of stroke survivors

Novel technology to diagnose Alzheimer's disease before symptoms appear

Study: Young survivors covered by Medicare Part D often can't afford stroke medications

JDR releases research report on Osteonecrosis of the jaw

Phase III RISE study of Lucentis for DME meets primary endpoint

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

CX3CL1 signaling chemical can offer better understanding of Parkinson's disease

Some fat is essential for body function

Study explores levels of burden and depression in caregivers with sensory impairment

UH Case Stroke and Cerebrovascular Center increases tPA use for ischemic stroke by 13.5 times

New study establishes link between coronary artery disease and genetic susceptibility

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Latest News